Frequency of Allergies to Fosfomycin
Allergic reactions to fosfomycin are extremely rare, with serious hypersensitivity reactions including anaphylaxis and angioedema reported only infrequently in post-marketing surveillance, and no specific frequency data available in the literature.
Clinical Context and Evidence
The available evidence regarding fosfomycin allergy frequency is notably limited compared to other antibiotics. The FDA drug label 1 indicates that during clinical trials involving 1,233 patients, no allergic reactions were reported among the most common adverse events (which occurred at >1% frequency). Post-marketing surveillance has identified rare cases of angioedema and anaphylaxis, though causality has not been definitively established and no specific incidence rates are provided 1.
Comparative Perspective
To contextualize fosfomycin's allergy profile:
- Fluoroquinolones: Anaphylaxis occurs at 1-5 per 100,000 prescriptions, with moxifloxacin most commonly implicated 2
- Macrolides: IgE-mediated reactions are uncommon and limited to case series, with anaphylaxis being extremely rare 2
- Fosfomycin: Falls into the category of antibiotics with the lowest reported allergy rates
A comprehensive FDA Adverse Event Reporting System (FAERS) analysis 3 examining fosfomycin safety did not identify hypersensitivity reactions as a significant safety signal. The disproportionality analysis found higher than expected frequencies of agranulocytosis, liver injury, and severe skin reactions, but subsequent detailed analysis did not confirm these associations as true safety signals.
Documented Adverse Events
The most common adverse effects of fosfomycin are non-allergic in nature 1:
- Gastrointestinal disturbances (diarrhea 9-10%, nausea 4-5%)
- Vaginitis (5.5%)
- Headache (3.9%)
A Japanese post-marketing surveillance study 4 of 35,481 cases found that among 83 patients with beta-lactam hypersensitivity who received oral fosfomycin, gastrointestinal side effects occurred but none developed hypersensitivity or allergic reactions.
Severe Cutaneous Reactions
A recent case-crossover study 5 examining Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) found an odds ratio of 5.40 (95% CI: 1.20-30.97) for fosfomycin, with a cumulative incidence below 10.0 per 100,000 new users. However, this represents severe cutaneous reactions rather than typical IgE-mediated allergies.
Clinical Implications
Fosfomycin can be considered one of the safest antibiotics from an allergic reaction standpoint, particularly useful for:
- Patients with multiple antibiotic allergies
- Beta-lactam allergic patients requiring urinary tract infection treatment
- Situations where minimizing allergic risk is paramount
Important Caveats
Lack of cross-reactivity data: Unlike beta-lactams or fluoroquinolones, there is no established cross-reactivity pattern with other antibiotic classes 4
Rare but serious reactions exist: While extremely uncommon, post-marketing reports include angioedema and anaphylaxis 1
Agranulocytosis: Though not an allergic reaction, rare cases of agranulocytosis (possibly immune-mediated) have been reported with parenteral fosfomycin 6
No validated skin testing: Unlike penicillins, there are no validated skin testing protocols for fosfomycin allergy
In clinical practice, fosfomycin's allergy risk is so low that it should not be a significant consideration when selecting this antibiotic for appropriate indications, particularly uncomplicated urinary tract infections.